|Bid||12.44 x 4000|
|Ask||12.46 x 2200|
|Day's range||10.52 - 12.40|
|52-week range||2.28 - 33.79|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Earnings date||09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.71|
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were jumping 10.5% as of 11:07 a.m. EST on Friday. Positive phase 2 results will also be necessary to advance the experimental COVID-19 vaccine into late-stage testing.
Now that Moderna and Pfizer have both announced that their coronavirus vaccine candidates appear to be effective at preventing infection, distant laggards look less desirable than ever. Inovio Pharmaceuticals (NASDAQ: INO), Vaxart (NASDAQ: VXRT), and Novavax (NASDAQ: NVAX) aren't going to start selling their candidates to the public anytime soon, but they could still be lucrative stocks. All three have moved more slowly than Moderna and Pfizer, but they share one of the same challenges.
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sliding 5.2% lower as of 3:45 p.m. EST on Friday. The company announced earlier in the day that positive results from a phase 2 study evaluating INO-5401 and INO-9012 in combination with cancer immunotherapy Libtayo will be presented at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting. In addition, investors appear to be much more heavily focused on Inovio's COVID-19 program than anything else right now.